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A B S T R A C T
Purpose: To extend our knowledge and practical application of the concept of catamenial epilepsy.
Methods: The review focuses on the impact of the NIH Progesterone Trial on our understanding of the
pathophysiology and treatment of catamenial epilepsy.
Results: Catamenial epilepsy refers to the cyclic exacerbation of seizures in relation to the menstrual
cycle. An interaction between seizures and the menstrual cycle is suggested by variations in seizure
frequency according to the day, phase and ovulatory status of the menstrual cycle. There are three
commonly recognized patterns: perimenstrual (C1: Day 3 to +3), peri-ovulatory (C2: Day 10 to 3) and
entire luteal phase in anovulatory cycles (C3: Day 10 to 3). Pathophysiological determinants include 1)
the neuroactive properties of reproductive steroids, 2) the variation of neuroactive steroid levels across
the menstrual cycle and 3) the differential susceptibility of epileptic substrates to neuroactive steroid
effects. Perimenstrual seizure exacerbation may result from the premenstrual withdrawal of
progesterone which is accompanied by withdrawal of allopregnanolone, a potent positive allosteric
modulator of the GABAA receptor, and changes in the subunit composition of the GABAA receptor to the
a4 subtype which is insensitive to benzodiazepine and GABA. Bioidentical progesterone supplement is
no better than placebo in the treatment of women with focal onset epilepsy overall but shows superior
efﬁcacy in women whose seizures show robust perimenstrual exacerbation.
Conclusion: There is sound evidence for the existence of catamenial epilepsy and class 3 evidence for
adjunctive progesterone treatment of the perimenstrually exacerbated subtype.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
The term ‘‘catamenial epilepsy’’ refers to cyclic seizure
exacerbation in relation to the menstrual cycle [1,2]. Although
generally supportive evidence has been mounting since 1881 when
William Gowers published his observation that the majority of the
women in his clinic reported worsening of seizures perimenstru-
ally [3], there is still some controversy regarding the existence and
prevalence of catamenial epilepsy. Differences in opinion stemAbbreviations: C1, perimenstrual (Days 3 to +3); C2, peri-ovulatory (Days 10
to 13); C3, luteal in anovulatory cycles (Days 10–3).
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights relargely from differences in the deﬁnitions of catamenial epilepsy
that investigators have used for designation. The concept of
catamenial epilepsy is based principally on three pathophysiologi-
cal determinants: (1) the neuroactive properties of reproductive
steroids, (2) the variation of neuroactive steroid levels across the
menstrual cycle and (3) the susceptibility of the epileptic substrate
to neuroactive steroid effects [1,2]. If reproductive steroids have a
role in seizure occurrence, it follows that reproductive steroids
may also have a role in treatment. Yet, despite the 30% prevalence
of individuals with intractable seizures [4], hormonal treatment
trials have been lacking. The purpose of this review is to discuss
how the ﬁndings of the NIH Progesterone Trial, the ﬁrst large-scale,
randomized, placebo controlled, multicenter hormonal treatment
trial, may contribute to our understanding and practical applica-
tion of the concept of catamenial epilepsy [5].served.
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Fig. 1. The distribution of seizure numbers varies across the days of the menstrual
cycle (nested repeated measures ANOVA for the number of seizures on each day,
p < 0.0001).
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2.1. Periodicity of seizures
Comprehensive management of epilepsy may need to
consider how seizures vary over time. Chronobiology, that
investigates how physiological and pathological processes vary
over time, has identiﬁed circadian rhythms that approximate
the 24-h day length (e.g. wake-sleep cycles), ultradian rhythms
that have periodicities that are much shorter than 24 h (e.g. the
pulsatile secretion of gonadotropin releasing hormones, sleep
cycles), and infradian rhythms that have periodicities that are
much longer than 24 h (e.g. the menstrual cycle) [6,7]. Some
infradian rhythms synchronize with or are entrained by
external astronomical factors such as lunar (e.g. menstrual
cycle) and solar (e.g. seasonal affective disorders) cycles
[7]. There is evidence to suggest that seizures may show a
circadian rhythm with predilection for occurrence at various
times of the day or night [8–10]. Further, the time of
predilection may vary with the location of the epileptic focus,
e.g. nocturnal predilection of frontal lobe epilepsy versus
morning and afternoon occurrence of temporal lobe seizures
[8–10]. There is also evidence that seizure occurrence may
show a circalunar periodicity. This may occur not only in 35% of
women in relation to their menstrual cycles but also in 29% of
men who show predilection for seizure occurrence at 3–6 week
intervals [11]. The NIH Progesterone Trial investigated the
periodicity of seizure occurrence in women with epilepsy
[5]. The women, 13–45 years of age, had intractable focal onset
seizures. They recorded the number of seizures that they had
each day and the day of each menstrual onset during the
3-month baseline phase. Statistical analysis of the data using a
cosinor method that ﬁtted the daily seizure numbers to a sine
wave using the method of least squares in order to identify any
periodicity of seizure frequency and the ‘‘strength’’ of the
periodicity as determined by its level of statistical signiﬁcance,
found that seizures in both ovulatory and anovulatory cycles
showed circalunar periodicities of 28 days but anovulatory
cycles also showed periodicities of 14 and 9 days [7]. These
ﬁndings support the notion that the lunar cycle inﬂuences
seizure occurrence. The lunar periodicity of menstrual cycles
and seizures represent either a parallel but independent effects
of the lunar cycle or parallel effects of the lunar cycle with
interaction between seizures and the menstrual cycle. Differ-
ences in periodicities between ovulatory and anovulatory
cycles would suggest the latter.
2.1.1. Day-by-day comparisons of seizures across the menstrual cycle
The NIH Progesterone Trial carried out day-by-day compar-
isons of all menstrual cycle days for seizure numbers and seizure
occurrence regardless of numbers [12]. Results for average daily
seizure frequency are presented in Fig. 1. The results of day-by-
day comparisons are presented in color coded nomograms
(Figs. 2 and 3). The highest average daily seizure frequency and
the day with the greatest likelihood of seizure occurrence was on
Day 1 of the cycle, i.e. the day of menstrual onset, and the lowest
on Day 8, i.e. during the midluteal phase. Seizure numbers were
two times greater on Day 1 (average daily seizure frequency:
0.68) than on Day 8 (0.30). Likewise, seizure occurrence
regardless of numbers were two times more likely on Day 1
(0.33) than on Day 8 (0.17). These ﬁndings are consistent with a
number of previous studies that have shown greater seizure
frequency perimenstrually than at other times during the
menstrual cycle and the fewest seizures on a mid luteal day
[3,13–15].2.2. Phase by phase comparisons of seizures across the menstrual
cycle
The menstrual cycle consists of follicular and luteal phases
which are divided by the principal events of the menstrual cycle,
ovulation and menstruation [1]. These events are heralded by
major changes in hormonal levels: a pre-ovulatory surge in
estradiol levels and a premenstrual drop in progesterone levels
[1]. On the basis of the neuroactive properties of estradiol and
progesterone and the changes in their serum levels across the
menstrual cycle, especially the proconvulsant effects of the
estradiol surge and the anticonvulsant effects of progesterone
withdrawal, one can further divide the cycle into 4 phases to
determine whether, in fact, there is an increase in seizures during
the peri-ovulatory and perimenstrual phases in comparison to the
intervening mid-follicular and mid-luteal phases that could be
used as baseline comparators [1,2]. Speciﬁcally, seizures would be
more likely to occur perimenstrually, deﬁned in our 1997
investigation arbitrarily as Days 3 to 3 and identiﬁed as
catamenial type 1 or C1 pattern and during or right after the
pre-ovulatory estradiol surge between Days 10 to 13, identiﬁed
as catamenial type 2 or C2 pattern, than during the remainder of
the cycle, i.e. mid follicular phase (Days 4–9) and mid luteal phase
(Days 12 to 4) [1]. The investigators proposed that anovulatory
cycles, by virtue of having higher estradiol to progesterone level
ratios during the luteal phase, would show a different pattern of
seizure exacerbation in comparison to ovulatory cycles with more
seizures from the time of the preovulatory estradiol surge though
the perimenstrual phase as compared to the mid follicular phase
(Days 4–9). The 1997 study enrolled 184 women with intractable
seizures of focal onset and compared seizure frequencies across the
various phases of the menstrual cycle during a single cycle. It
showed statistically signiﬁcant support for the greater occurrence
of seizures according to the C1 and C2 patterns during ovulatory
cycles and the C3 pattern during anovulatory cycles (Fig. 4). The
NIH Progesterone Trial investigated the rationale for the separate
consideration of ovulatory and anovulatory cycles. Anovulatory
cycles differ from ovulatory cycle by their lack of progesterone
secretion during the luteal phase which generally yields high
proconvulsant estradiol to anticonvulsant progesterone serum
level ratios throughout the luteal phase which, unlike ovulatory
cycles, would then be expected to result in greater seizure
frequency throughout the luteal phase. The NIH Progesterone Trial
investigated the sensitivity and speciﬁcity of the 3 patterns in
Fig. 2. Directional changes and levels of statistical signiﬁcance of comparisons of each day in the columns with each day in the rows are presented as a color coded nomogram
with legend. The nomogram shows signiﬁcantly more seizures occurring on Day 1 and fewer seizures on Day 8 of the cycle as compared to most other days of the cycle.
Fig. 3. Directional changes and levels of statistical signiﬁcance of comparisons of each day in the columns with each day in the rows are presented as a color coded nomogram
with legend. The nomogram shows that the likelihood of seizure occurrence is signiﬁcantly greater on Day 1 and less on Day 8 of the cycle as compared to most other days of
the cycle.
A.G. Herzog / Seizure 28 (2015) 18–2520distinguishing ovulatory from anovulatory cycles in the ﬁrst
100 enrolled subjects [16]. Retention during baseline phase was
80%. Complete data were available for 157 cycles at the time of
analysis. A midluteal progesterone level 5 ng/ml was used to
identify ovulatory cycles. The study found that the association
between C1 or 2 patterns and ovulatory cycles showed an 82.4%
sensitivity and 95.7% speciﬁcity whereas the association between
the C3 pattern and anovulatory cycles showed 76.2% sensitivity
and 40.0% speciﬁcity. Ovulatory cycles which showed the C3
pattern had signiﬁcantly higher mid luteal serum estradiol (pg/
ml)/progesterone (ng/ml) ratios than those that showed C1 and/or
2 patterns: 12.5  5.6 versus 8.0  3.7. The lack of speciﬁcity of the
C3 pattern for anovulatory cycles was not predicted and suggests that
ovulatory, as well as anovulatory cycles, can show the C3 pattern if
they have high mid luteal estradiol/progesterone ratios. Although the
C3 pattern is not considered by the Herzog et al. 1997 criteria for
catamenial designation in ovulatory cycles, the great majority (83.3%)
of these ovulatory cycles, nevertheless, were still categorized as being
catamenial on the basis of demonstrating the C1 or C2 patterns. Of
note, C1 and C2 patterns coexist with each other in the same cycle in
only 33.3% of ovulatory cycles that show one or other pattern.2.3. Prevalence of catamenial epilepsy
The prevalence of catamenial epilepsy is a function of the
deﬁnition that investigators utilize for designation [1,2]. Speciﬁ-
cally, investigations have differed in the deﬁnition of the phase of
the cycle with seizure exacerbation under consideration, as well as
the cutoff levels for seizure increase required for designation. The
Herzog et al. 1997 investigation demonstrated a relationship
between the proportion of women who showed one of the patterns
of catamenial exacerbation and the level of seizure exacerbation
expressed as multiples of the average daily seizure frequencies
during the phase of exacerbation relative to baseline comparator
phases, i.e. the mid-follicular and mid-luteal phases for ovulatory
cycles and the mid follicular phase for anovulatory cycles [1]. The
relationship took the form of reverse S-shaped curves for each of
the three patterns of catamenial exacerbation. This relationship
suggested that there were large proportions of women with
epilepsy who manifested some level of each of these patterns of
catamenial seizure exacerbation and small proportions who had a
high level of each of these patterns of catamenial seizure
exacerbation. The points of inﬂection of these reverse S-shaped
0.3
0.4
0.5
0.6
0.7
Menst
-3 to  +3
Follic
4 to  9
Ovul
10 to  -1 3
Luteal
-12 to -4
Av
g 
N
o
.
 
Se
iz
u
re
s 
/ D
ay
Ovulatory Cycles N = 98
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Menst
-3 to  +3
Follic
4 to 9
Ovul
10 to  -1 3
Luteal
-12 to -4
Av
g 
N
o
.
 
Se
iz
u
re
s
 
/ D
a
y Anovulatory Cycles N = 86
C1
C2
C3
Three Patterns of Catamenial Epilepsy
Fig. 4. Phase by phase comparisons of average daily seizure frequency across the
menstrual cycle shows signiﬁcantly more seizures during the perimenstrual
(p < 0.001) and peri-ovulatory (p < 0.001) phases than during the mid-follicular
and mid-luteal phases during ovulatory cycles, lending statistical support for the
existence of the C1 and C2 patterns of catamenial seizure exacerbation in ovulatory
cycles and signiﬁcantly more seizures during the peri-ovulatory, mid-luteal and
perimenstrual phases combined (p < 0.001) than during the mid-follicular phase in
anovulatory cycles, lending support for the existence of the C3 pattern in
anovulatory cycles.
A.G. Herzog / Seizure 28 (2015) 18–25 21curves (C1: 1.69, C2–1.83 and C3–1.62) were determined and are
considered to be the mathematically optimal cutoffs for exacerba-
tion levels that distinguish women whose seizures show substan-
tial versus little hormonal sensitivity.
Using the cutoffs provided by the points of inﬂection of the
3 reverse S-shaped curves for the designation of catamenial
epilepsy, the 1997 investigation found that 78 of the 184 or 42.3%
of the women demonstrated at least one of the 3 patterns of
catamenial epilepsy (ovulatory cycles: C1–35.7%, C2–28.5%; and
anovulatory cycles: C3–41.4%) [1]. The reverse S-shaped curves
also help to reconcile some apparent discrepancies in past reports
regarding the prevalence of catamenial epilepsy. Speciﬁcally the
ﬁndings of a high prevalence reported in investigations by Tauboll
et al. – 78% [17], Laidlaw – 72% [14], Rosciszewska – 67% [18] and
Ansell and Clarke–63% [19], all of whom deﬁned catamenial
epilepsy in terms of just more seizures perimenstrually as
compared to other phases of the cycle, corresponded closely with
our ﬁnding of 71.4% that fell at the high end of the curve for
perimenstrual exacerbation, whereas the ﬁnding of Duncan et al.
(12.5%) [20] who required a 6-fold increase in average daily seizure
frequency for designation (i.e. that 3/4 of seizures occur between
Days 5 and 5 which is approximately one-third of an average
cycle) was consistent with the low end plateau found in the curve
at approximately 10% for threefold or greater seizure increase.
Using these cutoffs for the designation of catamenial epilepsy
and the requirement that one or more be present in at least 2 of the
3 baseline cycles, the NIH Progesterone Trial found that 44.2% of
the 294 randomized subjects who completed the 3-month baseline
phase could be categorized as having catamenial epilepsy [5]. The
prevalence of catamenial epilepsy by pattern was as follows: C1
pattern seizure exacerbation occurred in 39.8%, C2 pattern in 33.9%
and C3 pattern, in 47.1%. These values compare quite closely to theﬁndings of the 1997 study which, using the same cutoffs, showed
the C1 pattern of seizure exacerbation in 35.7%, the C2 pattern in
28.5% and the C3 pattern in 41.4% of anovulatory cycles
[1]. Enrollment bias for a hormonal treatment trial may account
for the somewhat higher values in the NIH Progesterone Trial.
3. Pathophysiology of catamenial epilepsy
There are three critical pathophysiological determinants of
catamenial epilepsy: (1) neuroactive properties of reproductive
steroids, (2) variation of neuroactive steroid levels across the
menstrual cycle and (3) susceptibility of the epileptic substrate to
neuroactive steroid effects [1,21,22].
3.1. Neuroactive properties of reproductive steroids
The most consistent and compelling preclinical evidence with
regard to the neuroactive properties of reproductive steroids that
may be pertinent to catamenial epilepsy is that progesterone has a
reduced metabolite, allopregnanolone, that is a potent positive
allosteric modulator of GABAA neurotransmission [23,24] and that
the withdrawal of progesterone or allopregnanolone, such as may
occur premenstrually, changes GABAAR subunit composition to the
a4d subtype which is insensitive to benzodiazepine and GABA but
remains sensitive to neurosteroid [25,26]. This would provide a
mechanism for perimenstrual seizure exacerbation and a rationale
for treatment trials with cyclic progesterone supplement that
include gradual, rather than abrupt, progesterone withdrawal
premenstrually.
The neuroactive properties of estradiol may also be pertinent.
The potential importance of estradiol in the regulation of
temporolimbic function is highlighted by the presence of the
estradiol synthesizing enzymes, cytochromes P45017a and P450
aromatases, that are localized in neurons in the hippocampus and
the measurement of hippocampal estradiol levels that surpass
serum levels [27,28]. The pertinent actions of estradiol, however,
are not as clear as for progesterone. Historical investigations have
demonstrated the complexity of estrogen effects and the impact of
the estrogen concentration, mode and site of administration,
blood–brain barrier and epileptic substrate [29]. Apparently
contradictory effects of estrogen in the brain are reviewed in
detail by Veliskova et al. [30]. Assuming a proconvulsant effect of
estradiol, mid cycle seizure exacerbation correlates temporally
with and could result from the pre-ovulatory estradiol surge
[1,2]. Entire luteal phase seizure exacerbation in anovulatory
cycles and ovulatory cycles with high serum estradiol to
progesterone level ratios could result from unopposed estradiol
effect. In favor of a proconvulsant effect, estradiol potentiates a
number of animal kindling paradigms [31]. Estradiol potentiates
depolarizing responses to iontophoretic pulses of exogenous
glutamate [32,33]. By way of underpinnings for this neuroexci-
tatory effect, there are a number of proposed candidate mecha-
nisms. Estradiol may potentiate neuronal excitability by regulating
neuronal plasticity, speciﬁcally by increasing the density of NMDA
receptor-containing synapses on the apical dendrites of hippo-
campal CA1 pyramidal neurons via an N-methyl-D-aspartate
receptor-dependent mechanism [34,35]. Estradiol, however, may
also potentiate kainate, and quisqualate mediated neurotransmis-
sion, thereby implicating non-NMDA receptors in the short-term
action of estrogen. Speciﬁcally, estradiol can produce a rapid and
reversible increase in the amplitude of the Schaffer collateral-
activated EPSP which can be blocked by non-NMDA, but not
NMDA, antagonists [36,37]. A non-NMDA mechanism of action is
supported by a more recent preclinical model which suggests that
E2 binds ERbR to increase glutamatergic AMPAR mediated EPSPs
[37] and binds ERaR to acutely suppress presynaptic GABA release
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complex role of estrogen, however, is illustrated by evidence in
some models that estradiol can raise seizure thresholds in the
hippocampal region and provide neuroprotection against seizure
induced injury [39].
3.2. Differences in seizure frequency between ovulatory and
anovulatory menstrual cycles
The NIH Progesterone Trial ﬁndings provide additional support
for the potential importance of neuroactive steroids. One of the
tertiary outcomes of the trial was to determine whether seizure
frequency differs between anovulatory and ovulatory cycles [40].
92 of the women had at least one ovulatory and one anovulatory
cycle during the 3 baseline months of the trial. Serving as their own
controls, paired t-tests showed a statistically signiﬁcantly greater
secondary generalized tonic–clonic seizure average daily seizure
frequency by 29.5% during their anovulatory cycles as compared to
their ovulatory cycles. Complex partial and simple partial seizure
frequencies did not differ signiﬁcantly. For secondary generalized
tonic–clonic seizures, the proportional differences in anovulatory/
ovulatory average daily seizure frequency ratios correlated
signiﬁcantly with differences in mid-luteal anovulatory/ovulatory
estradiol/progesterone serum level ratios. These ﬁndings support a
possible role for reproductive steroid levels and ratios in secondary
generalized tonic–clonic seizure occurrence. The ﬁnding of greater
seizure frequency in anovulatory than ovulatory cycles is
consistent with our past report as well as the reports of others
[1,13,41].
3.3. Epilepsy substrates and the effects of epilepsy laterality and
focality on the prevalence of catamenial epilepsy
Epileptic brain substrates differ from non-epileptic brain at
the molecular biological (e.g. GABAARs) as well as gross
anatomical (e.g. mesial temporal sclerosis, heterotopias) levels.
At the molecular biological level, for example, GABAARs in the
molecular layer of the dentate gyrus in a rat model of epilepsy
differ from controls in that they have a preponderance of a4 g2
subunits which are insensitive to both BDZ and neurosteroids
since benzodaiepines lack activity at receptors that have the a4
subunit and neurosteroids preferentially bind the d subunit
[42]. Brain substrates may also show differential propensity for
catameniality. As one of its tertiary outcomes, the NIH
Progesterone Trial investigated whether the laterality and
focality of the epileptic foci were factors in catameniality in
the ﬁrst 100 subjects who completed the baseline phase
[22]. Principal investigators at each site determined the laterality
and focality of the epileptic foci on the basis of all available
pertinent clinical data and neurological tests including EEG, EEG
monitoring, MR cranial imaging, interictal and ictal SPECT and
PET. Of the 100 subjects, 71 were identiﬁed as having temporal
lobe (left = 25, right = 29, bilateral = 17), 10 extratemporal, 14
mixed, and 5 indeterminate seizure foci. Extratemporal and
mixed seizures occurred randomly across the cycle. Cosinor
analysis determined the existence of periodicities of seizures
during the three month baseline phase. Temporal lobe seizures
(left = 875, right = 706) did not show a random distribution.
Temporal lobe seizures occurred cyclically at intervals of 27 days
with peak occurrence near the onset of menses. Laterality was a
factor. Left-sided temporal lobe seizures occurred maximally and
cyclically at onset of menses, whereas right sided temporal lobe
seizures occurred randomly. This investigation determined that
the circalunar rhythms of seizures in women vary with the
neuroanatomic substrate of the seizure focus. Temporal lobe
seizures, especially left-sided foci, are more susceptible tocircalunar rhythmic occurrence than those arising from extra-
temporal or mixed foci.
4. Treatment
The NIH Progesterone Trial was a randomized, placebo-
controlled, double-blind, clinical trial of progesterone versus
placebo therapy in the treatment of intractable seizures in women
with and without catamenial epilepsy [5]. The principal outcomes
were the proportion of 50% responders and the change in seizure
frequency between the 3-month baseline and 3-month treatment
phases. Sample size of 640 was determined as the enrollment
requirement to show a signiﬁcant difference (p  .05) between
treatments for 50% responders with 80% power for 35%
progesterone versus 15% placebo responders in the catamenial
stratum. The large sample size was required since only about one-
third of the women were expected to show a catamenial pattern of
seizure exacerbation. Catamenial designation was based on the
demonstration of catameniality in 2 of 3 baseline cycles using the
Herzog et al. [1] established points of inﬂection cutoffs for
designation of C1–C3 patterns. The trial enrolled only 462 women
and randomized the 294 subjects who completed the baseline
phase. Randomization was carried out seprarately for the
catamenial and non-catamenial strata, 2:1 to progesterone or
matching placebo treatment. Treatment regimen consisted of
baseline optimal antiepileptic drug treatment plus adjunctive
progesterone 200 mg lozenges or matching placebo. A whole
lozenge was taken three times daily on days 14–25, ½ lozenge
three times daily on Days 26–27, ¼ lozenge taken three times daily
on Day 28 and then no lozenges until the next Day 14.
The ﬁndings of the NIH Progesterone Trial showed that cyclic
progesterone is comparable to placebo in the treatment of
intractable seizures in women with partial epilepsy [5]. A pre-
speciﬁed secondary analysis identiﬁed a subset of women with
perimenstrual seizure exacerbation who were responsive to
progesterone treatment. This post hoc predictor analysis using
binary logistic regression analysis (dependent variable being 50%
progesterone responder: yes or no) found that the level of
perimenstrual catameniality (C1 level) is a predictor of the efﬁcacy
of progesterone treatment. There was a signiﬁcant interaction
between C1 level and treatment. With increasing C1 levels,
responder rates increased progressively from 21.3 to 57.1% for
progesterone versus only 19.6% to 20.0% with placebo
(Fig. 5A). Changes in average daily seizure frequency progressed
from 25.5 to 71.0% for progesterone versus only 25.0 to
26.3% for placebo (Fig. 5B). There was also signiﬁcant interaction
between C1 level and progesterone treatment for the most severe
seizure type, secondary generalized tonic–clonic seizures and
complex partial seizures but not simple partial seizures. The
separation between responder rates for all seizures combined for
progesterone (27.3%) versus placebo (14.3%) treatments was not
signiﬁcant at C1 level 1.69, the C1 cutoff level selected for
designation to the catamenial stratum. The separation did achieve
statistical signiﬁcance at C1 level 2 (28.6% versus 12.9%) and at C1
level 3, the separation (37.8% versus 11.1%) was both signiﬁcant
(p = .0372) and achieved the anticipated clinically important
separation goal of the trial, i.e. 35% responder rate for
progesterone versus 15% responder rate for placebo.
In the Trial [5], 38.1% of the subjects had C1 level 1.69, 34.4%
had C1 level 2 and 21.4% had C1 level 3 levels of perimenstrual
exacerbation (Table 1). Of note, 12.2% had C1 level 6 which is
almost identical to the 12.4% found in the Duncan study (Table 1)
[20]. The ﬁndings suggest that 21.4% of women with intractable
seizures, i.e. the percent that had C1 level 3 baseline, might be
candidates for cyclic progesterone supplement.
Fig. 5. (A) Percent 50% Responders in Relation to C1 Level: Progesterone versus
Placebo.
This is a plot of 50% responders versus the level of perimenstrual seizure
exacerbation (C1 level). C1 levels were determined during baseline and are
expressed as multiples of the combined mid-follicular and mid-luteal seizure
frequencies. Each level includes all women who had seizure exacerbation greater
than or equal to that speciﬁc level of catameniality. With increasing C1 levels, the
rate of 50% responders increased from 21.3% to 57.1% with progesterone
treatment as compared to an increase of only 19.6% to 20.0% with placebo
treatment. The anticipated primary outcome that 35% of catamenial progesterone
treated versus 15% of placebo treated women would show a 50% reduction in
seizure frequency is realized at C1 level 3 where 37.8% of progesterone treated as
compared to 11.1% of placebo treated women were 50% responders (p = .0372). In
comparison to the responder rate of the combined placebo group, the progesterone
responder rates are signiﬁcantly greater at each C1 level 3. (B) Percent Change in
Average Daily Seizure Frequency in Relation to C1 Level: Progesterone versus
Placebo. With increasing C1 levels from 1 to 10, the percent reduction in ADSF
(mean  SEM) progressed from 25.5% to 71.0% for progesterone as compared to 25.0–
26.2% for placebo. Separation between the treatments reached signiﬁcance at C1 levels
4. In comparison to change in ADSF in the combined placebo group, the changes in
ADSF in progesterone treated subjects are signiﬁcant at each C1 level 3. Prog,
progesterone; Plac, placebo; C1, perimenstrual seizure exacerbation.
Table 1
Percent of women with various levels of perimenstrual seizure exacerbation.
C1 level # WWE % WWE
0 294 100.00
1 196 66.67
1.69 112 38.10
2 101 34.35
3 63 21.43
4 51 17.35
5 44 14.97
6 36 12.24
7 31 10.54
8 24 8.16
9 22 7.48
10 19 6.46
C1 level, level of perimenstrual seizure exacerbation; WWE, women with epilepsy.
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allopregnanolone (AP) may mediate seizure reduction in proges-
terone treated women with epilepsy [43]. AP levels were
signiﬁcantly greater in treated than in baseline cycles for women
treated with progesterone but not placebo, regardless of catame-
nial designation. There was a signiﬁcant inverse correlation
between changes in seizure frequency and changes in AP levelsfor the subset of subjects who showed a signiﬁcantly greater
responder rate in the post hoc analysis of the trial, i.e. subjects who
had a threefold or greater increase in average daily seizure
frequency perimenstrually as compared to the mid follicular and
mid luteal phases (C1 3): r = 0.442, p = .013 and speciﬁcally for
C1 3 progesterone treated subjects (r = 0.452, p = .035), but not
other groups (C1 3 placebo: r = 0.318, C1 <3 progesterone:
r = 0.099, C1 <3 placebo: r = 0.131; p = NS). The ﬁndings support AP
as a mediator of seizure reduction in progesterone treated women
who have a substantial level of perimenstrually exacerbated
seizures.
Failure of the trial to prove the principal hypothesis may relate
to the design that attempted to treat 3 patterns of catamenial
epilepsy which likely differ in pathophysiology with a single
treatment regimen [1,2,5]. Speciﬁcally, cyclic progesterone sup-
plement may have greater efﬁcacy where progesterone withdraw-
al (C1 pattern), rather than estrogen surge (C2) or high luteal phase
estradiol/progesterone serum level ratios (C3 pattern), are causally
implicated. The design also assumed that the mathematically
determined cutoff for catamenial designation would match the
cutoff for a signiﬁcant progesterone response. The absence of a
signiﬁcant difference between progesterone and placebo respond-
ers at the C1 cutoff level of 1.69 and ﬁnding of a signiﬁcant
difference at a clinically important level at C1 level 3 may suggest
that there is a difference between the catamenial level that
mathematically best distinguishes hormonally sensitive seizures
and the level that distinguishes progesterone responders at a
statistically signiﬁcant and clinically important level. Actual
enrollment of a larger sample size might have achieved a
signiﬁcant difference, i.e. 234 progesterone and 117 placebo-
treated subjects might show the demonstrated C1 1.69
progesterone responder rate of 27.3% versus placebo rate of
14.2% with p  0.05 and power of .80. Even with these larger
numbers, however, the responder rate would still not achieve what
we considered to be a clinically important response level of 35%.
Progesterone is a naturally occurring hormone with a long
history of clinical use for the treatment of reproductive disorders,
e.g. inadequate luteal phase cycles, infertility and postmenopausal
hormone replacement [44]. Its safe use during pregnancy has been
well documented [44]. This novel use of cyclic progesterone
supplement as a treatment for women with epilepsy showed a
favorable short term safety proﬁle that did not differ signiﬁcantly
from placebo in the frequency and types of adverse events [5]. The
proﬁle is also favorable in comparison to AEDs. There were 22
serious adverse events (SAEs) among the 462 women, 13 during
baseline and 9 during treatment. Of the 9 during the treatment
phase, 6 occurred on progesterone and 3 on placebo, commensu-
rate with the 2:1 randomization. The most common SAE (12/22)
was hospitalization for seizures: baseline phase – 7, treatment
A.G. Herzog / Seizure 28 (2015) 18–2524phase – 5; progesterone – 2, placebo – 3. Two subjects died, one in
baseline and one during treatment. The baseline death was by
suicide, committed after the initial visit. The treatment phase
death was attributed to SUDEP and considered unlikely to be
related to progesterone treatment. The 8 other SAEs had singular
occurrence. Five (nausea, fever and vomiting, cellulitis, insomnia,
AED overdose) occurred during baseline and 3 (stomach ﬂu,
thyroid carcinoma, blurred vision) on treatment, all on progester-
one but considered unlikely to be related to progesterone. There
were no signiﬁcant differences in proportions of occurrences of any
adverse event between the two treatment groups within either
stratum. Fatigue was the only adverse symptom that was reported
by >10% of subjects during the treatment phase (range 11.1–
16.5%) and the proportions were very similar in the progesterone
and placebo groups.
The practical applications are that the detection of a 3-fold
level of perimenstrual seizure exacerbation by charting of seizures
and menses might suggest a favorable response to treatment with
adjunctive cyclic progesterone supplement. The ﬁndings of the
secondary analysis still require formal conﬁrmation in an
adequately powered investigation of the derived hypotheses.
Periovulatory seizure exacerbation may not respond to progester-
one or may require the start of treatment earlier in the cycle than
Day 14 which was the start day in the NIH Progesterone Trial. Since
an earlier start to progesterone supplement may disrupt the
menstrual cycle and lead to intermenstrual bleeding, there may be
a role for the use of synthetic GABAergic steroids, analogs of
allopregnanolone such as ganaxolone that are devoid of reproduc-
tive hormonal properties and, therefore, can be used throughout
the cycle in women as well as in men [45]. Alternatively, perhaps a
more effective approach to suppression of the pre-ovulatory
estrogen surge may include parenteral treatment with depome-
droxyprogesterone [46] or GnRH analog with or without
hormonal supplement [47–49]. Investigations of these parenteral
treatments, however, have been limited to small open label trials
[46–49]. Finally, the role of progesterone treatment in primarily
generalized epilepsy, especially Juvenile Myoclonic Epilepsy, that
is more common in women and tends to develop in adrenarchal
and pubertal years, remains to be investigated.
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